secwatch.observer — SEC 8-K summary
======================================

Issuer:     Century Therapeutics, Inc. (IPSC)
CIK:        0001850119
Form:       8-K
Filed at:   2026-10-02T12:18:25+00:00
Accession:  0001104659-26-113055
Event type: other_material
Sentiment:  positive
Materiality: 0.45
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4.1-flash:cloud@v2

Century Therapeutics reports CNTY-813 nonclinical data at EASD; IND filing on track for Q4 2026
--------------------------------------------------------------------------------

- CNTY-813 maintained glycemic control in diabetic mice over an 11-month study until graft removal; all streptozotocin-induced diabetic mice dosed with CNTY-813 achieved normoglycemia.
- Five clinical-scale GMP batches produced consistent product via a 29-day process that exceeded purity criteria at every stage.
- Clinical-scale islets stored 96 hours cold normalized blood glucose in mice within 30 days and held normoglycemia through three months.
- Rat liver portal vein delivery yielded engraftment at one month, with islets staining positive for chromogranin A and insulin.
- CEO Brent Pfeiffenberger said the CNTY-813 IND submission remains on track for Q4 2026, with initial clinical data anticipated in 2H 2027.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1850119/000110465926113055/0001104659-26-113055-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1850119/000110465926113055/tm2626840d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-26-113055

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer